David Planchard

David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients

David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn:

“Great news, a new option in our 1st line strategy for NSCLC EGFRmut patients! To be discussed especially in our patients with brain metastases, ctDNA+ or high tumor load.”

David Planchard

Source: David Planchard/LinkedIn

.

cancer ctDNA David Planchard Gustave Roussy high tumor NSCLC EGFRmut OncoDaily Oncology thoracic oncologist